Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M208Revenue (TTM) $M--Net Margin (%)--Altman Z-Score11.5
Enterprise Value $M85.0EPS (TTM) $-1.5Operating Margin %--Piotroski F-Score3
P/E(ttm)--Beneish M-Score-3.0Pre-tax Margin (%)--Higher ROA y-yN
Price/Book1.510-y EBITDA Growth Rate %--Quick Ratio16.4Cash flow > EarningsY
Price/Sales--5-y EBITDA Growth Rate %7.4Current Ratio16.4Lower Leverage y-yY
Price/Free Cash Flow--y-y EBITDA Growth Rate %--ROA % (ttm)-41.0Higher Current Ratio y-yY
Dividend Yield %--PEG--ROE % (ttm)-45.5Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M50.6ROIC % (ttm)-305.1Gross Margin Increase y-yN

Gurus Latest Trades with CASC

Number of guru portfolios checked: 68.
Ticker Guru Date Action
Impact Price Range
(Average)*
Current Price Change from Average Comment Current Shares

CASC is held by these investors:



CASC: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Myers Scott DunsethPresident and CEO 2017-08-11Buy5,500$3.749.89view
Myers Scott DunsethPresident and CEO 2017-05-12Buy2,800$42.75view
Myers Scott DunsethPresident and CEO 2017-03-31Buy2,000$4.110view
Fyfe Gwen A.Director 2017-03-28Buy1,666$4.12-0.24view
Myers Scott DunsethPresident and CEO 2017-03-20Buy1,000$3.934.58view
LOVE TED WDirector 2017-02-02Buy23,000$4.24-3.07view
HENNEY CHRISTOPHER SDirector 2017-01-30Buy25,324$4.110view
Myers Scott DunsethPresident and CEO 2017-01-27Buy20,500$3.769.31view
Myers Scott DunsethPresident and CEO 2016-08-17Buy7,500$6.9-40.43view
Myers Scott DunsethPresident and CEO 2016-06-28Buy10,417$4.8-14.38view

Press Releases about CASC :

Quarterly/Annual Reports about CASC:

    News about CASC:

    Articles On GuruFocus.com
    Cascadian Therapeutics Announces FDA Orphan Drug Designation Granted to Tucatinib for the Treatment Sep 27 2017 
    Cascadian Therapeutics to Present at the Cantor Fitzgerald Global Healthcare Conference Sep 20 2017 
    Tucatinib Data in Multiple Tumor Types Presented at the European Society for Medical Oncology (ESMO) Sep 11 2017 
    Cascadian Therapeutics Announces Poster Presentations on Tucatinib in Multiple Tumor Types at the Eu Aug 28 2017 
    Cascadian Therapeutics Reports Second Quarter 2017 Financial Results Aug 08 2017 
    Cascadian Therapeutics to Report Second Quarter 2017 Financial Results on August 8, 2017 Aug 01 2017 
    Cascadian Therapeutics Announces Positive Regulatory Update for Tucatinib in Europe Jul 11 2017 
    Cascadian Therapeutics to Present at Jefferies 2017 Healthcare Conference May 31 2017 
    Cascadian Therapeutics Reports First Quarter 2017 Financial Results Conference Call Scheduled for To May 09 2017 
    Cascadian Therapeutics to Report First Quarter 2017 Financial Results on May 9, 2017 May 01 2017 
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

    GF Chat

    {{numOfNotice}}
    FEEDBACK